Grade My Investments
HomeFree Stock Grades › BCRX

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Grade

BCRX · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.6B
P/E Ratio
6.2
Revenue Growth (YoY)
+94.1%
Net Margin
30.2%
Return on Equity
Dividend Yield
None

About BioCryst Pharmaceuticals, Inc.'s fundamentals

BioCryst Pharmaceuticals is a small-cap biotech company with a market capitalization of $1.6 billion, currently trading at a P/E ratio of 6.2. The company demonstrated exceptional financial momentum with revenue growing 94.1% year-over-year and maintaining a net profit margin of 30.2%, indicating strong profitability relative to sales. BioCryst does not pay a dividend and lacks sufficient earnings history for a meaningful return on equity calculation.

Track BCRX free — no credit card required. Live grade + monthly AI report →